ANTIGEN BINDENDE PROTEINE

European patent · EP4034562 · In force

Register entry

Publication number
EP4034562
Application number
EP20789858
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Sep 25, 2020
Published
Aug 3, 2022
Granted
Oct 29, 2025
Protection ends at the latest
Sep 24, 2040
Next annual fee due
Sep 30, 2026
IPC classes
C07K 16/28 (2006.01)
A61P 35/00 (2006.01)
A61K 39/00 (2006.01)
Priority
US 201962906876 P 27.09.2019
US 202063057508 P 28.07.2020
PCT application
PCT/EP2020/076834 25.09.2020
PCT publication
WO2021/058711 01.04.2021
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Sep 9, 2026

    Change

    Published in Swissreg on 09.09.2026

  2. Oct 29, 2025

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 29.10.2025

Parties

Holder

GlaxoSmithKline Intellectual Property Development Limited

GSK Medicines Research Centre Gunnels Wood Road, Stevenage SG1 2NY, GB

Inventor

DEGENHARDT, Yan Y

Collegeville, Pennsylvania 19426, US

GUAN, Jun

Collegeville, Pennsylvania 19426, US

HANCE, Kenneth William

Collegeville, Pennsylvania 19426, US

MORLEY, Peter Joseph

Stevenage Hertfordshire SG1 2NY, GB

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.